A Look at Veliparib Plus Chemotherapy for First-Line Treatment of Advanced NSCLC
Ticiana Leal, MD+more
The strategy likely will not be pursued, however studies of PARP inhibitors plus immune checkpoint inhibitors are already in advanced stages. Read more
Study Provides Insights That May Inform Prevention, Management of Mesothelioma
Jian-fei Shen, MD, PhD+more
Analysis of worldwide epidemiologic patterns may help governments and medical institutions formulate targeted strategies for addressing mesothelioma. Read more
The FDA Explained: An Interview with Dr. Harpreet Singh
Lung Cancer ConsideredDuring an episode of IASLC’s Lung Cancer Considered podcast, Dr. Singh provided insight into the US agency’s approval process. Here are some highlights. Read more
A New Standard of Care in EGFR-Positive NSCLC Unresponsive to TKIs?
Myung-Ju Ahn, MD, PhDInterim analysis from ORIENT-31 demonstrates a four-drug regimen may be a reasonable option for patients whose disease has progressed on EGFR TKIs. Read more
The OncoKB Precision Oncology Knowledge Base: A Q&A with Dr. Debyani Chakravarty
Joy CurzioFinding precision treatments after molecular testing requires a tool for reviewing actionable mutations. Read more
Targeting Angiogenesis in Mesothelioma: Insights From MAPS and RAMES
Nirosha D. Perera, MD+more
Without validated biomarkers for anti-angiogenesis therapy, VEGF inhibitors are increasingly being investigated. Read more
Approval opens the door for an immunotherapy-based treatment option prior to surgery for the first time. Read more
Low-Dose CT, ctDNA May Partner for Lung Cancer Detection
Leah LawrenceLiquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT. Read more
Award Lecture Highlights Tumor Evolution Through Liquid Biopsy
Leah LawrenceThe UK’s Dr. Charles Swanton received the ISLB’s 2021 award for outstanding scientific contribution. Read more
Patient Perspective: Anxiety Follows Abrupt Departure From Clinical Trial
Julie Swedberg, CPAThe onboarding required to participate in a clinical trial is extensive. The offboarding, however, can feel like abandonment for some patients. Read more